Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott G Williams

Showing results (41-50 of 105) with videos related to

Pageof 11
Sort By:
BJU International|February 23, 2016
Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trialsMargaret Diana van Die, Kerry M Bone, Jon Emery, et al.
International Journal of Radiation Oncology, Biology, Physics|March 15, 2006
An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer riskScott G Williams, Gillian M Duchesne, N Kumar Gogna, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2008
In patients experiencing biochemical failure after radiotherapy, pretreatment risk group and PSA velocity predict differences in overall survival and biochemical failure-free intervalDaniel E Soto, Rebecca R Andridge, Charlie C Pan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 4, 2008
Determining if pretreatment PSA doubling time predicts PSA trajectories after radiation therapy for localized prostate cancerDaniel E Soto, Rebecca R Andridge, Charlie C Pan, et al.
International Journal of Radiation Oncology, Biology, Physics|May 10, 2011
High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trialMaroie Barkati, Scott G Williams, Farshad Foroudi, et al.
The Prostate|February 10, 2017
A Placebo-Controlled Double-Blinded Randomized Pilot Study of Combination Phytotherapy in Biochemically Recurrent Prostate CancerM Diana van Die, Scott G Williams, Jon Emery, et al.
International Journal of Radiation Oncology, Biology, Physics|November 6, 2017
The Transcriptional Landscape of Radiation-Treated Human Prostate Cancer: Analysis of a Prospective Tissue CohortSimon P Keam, Franco Caramia, Cristina Gamell, et al.
International Journal of Radiation Oncology, Biology, Physics|November 22, 2011
Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?Jiayi Huang, Frank A Vicini, Scott G Williams, et al.
The Primary Care Companion for CNS Disorders|May 17, 2021
Development of Insomnia Associated With Different Formulations of BupropionKamal Gandotra, George E Jaskiw, Scott G Williams, et al.
American Journal of Respiratory and Critical Care Medicine|August 22, 2025
Treatment Initiation as a Marker of Quality of OSA Care Among Active-Duty Military Personnel in the U.SEmerson M Wickwire, Vincent F Capaldi, Jeph Herrin, et al.
Pageof 11

Showing results (41-50 of 105) with videos related to

Sort By:
Pageof 11
BJU International|February 23, 2016
Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trialsMargaret Diana van Die, Kerry M Bone, Jon Emery, et al.
International Journal of Radiation Oncology, Biology, Physics|March 15, 2006
An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer riskScott G Williams, Gillian M Duchesne, N Kumar Gogna, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2008
In patients experiencing biochemical failure after radiotherapy, pretreatment risk group and PSA velocity predict differences in overall survival and biochemical failure-free intervalDaniel E Soto, Rebecca R Andridge, Charlie C Pan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 4, 2008
Determining if pretreatment PSA doubling time predicts PSA trajectories after radiation therapy for localized prostate cancerDaniel E Soto, Rebecca R Andridge, Charlie C Pan, et al.
International Journal of Radiation Oncology, Biology, Physics|May 10, 2011
High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trialMaroie Barkati, Scott G Williams, Farshad Foroudi, et al.
The Prostate|February 10, 2017
A Placebo-Controlled Double-Blinded Randomized Pilot Study of Combination Phytotherapy in Biochemically Recurrent Prostate CancerM Diana van Die, Scott G Williams, Jon Emery, et al.
International Journal of Radiation Oncology, Biology, Physics|November 6, 2017
The Transcriptional Landscape of Radiation-Treated Human Prostate Cancer: Analysis of a Prospective Tissue CohortSimon P Keam, Franco Caramia, Cristina Gamell, et al.
International Journal of Radiation Oncology, Biology, Physics|November 22, 2011
Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?Jiayi Huang, Frank A Vicini, Scott G Williams, et al.
The Primary Care Companion for CNS Disorders|May 17, 2021
Development of Insomnia Associated With Different Formulations of BupropionKamal Gandotra, George E Jaskiw, Scott G Williams, et al.
American Journal of Respiratory and Critical Care Medicine|August 22, 2025
Treatment Initiation as a Marker of Quality of OSA Care Among Active-Duty Military Personnel in the U.SEmerson M Wickwire, Vincent F Capaldi, Jeph Herrin, et al.
Pageof 11